Recombinant Human Monoclonal Antibody (RhuMAb)

Question

Recombinant human monoclonal antibody (rhuMAb)
A) appears promising as a treatment for asthma AND uses an engineered form of an IgG molecule.
B) promotes crosslinking between IgE molecules on the mast cells AND appears promising as a treatment for asthma.
C) appears promising as a treatment for asthma AND decreases the levels of IgG.
D) uses an engineered form of an IgG molecule AND promotes crosslinking between IgE molecules on the mast cells.
E) appears promising as a treatment for asthma AND uses an engineered form of an IgM molecule.

Accepted Answer

Recombinant human monoclonal antibody (rhuMAb) appears promising as a treatment for asthma and uses an engineered form of an IgG molecule. This is because rhuMAb targets specific proteins involved in the immune response, such as IgE or IL-5, to reduce inflammation in the airways of individuals with asthma. The engineered form of IgG is used to prolong the half-life of the antibody in the body, which allows for sustained treatment effects.